These become downregulated in a mouse Parkinson’s disease model with human SNCA overexpression, leading to enhanced GABAergic inhibition of DA release that will support DA release deficits.142 Thus, other networks operating at the level of DA axons might contribute to, or conversely partly mask, defective DA release in Parkinson’s disease. This evidence concerns the gene SNCA and Parkinson disease.